JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $836,000 | -3.5% | 18,281 | -5.3% | 0.85% | -19.4% |
| Q3 2017 | $866,000 | +102.3% | 19,301 | +34.9% | 1.06% | +63.6% |
| Q2 2017 | $428,000 | -21.3% | 14,307 | +7.0% | 0.65% | -5.5% |
| Q3 2015 | $544,000 | -20.6% | 13,376 | +4.1% | 0.69% | +1.3% |
| Q2 2015 | $685,000 | – | 12,850 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |